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DKK1 expression by synovial fibroblasts in
very early rheumatoid arthritis associates
with lymphocyte adhesion in an in vitro
flow co-culture system
Maria Juarez1†, Helen M. McGettrick1†, Dagmar Scheel-Toellner1, Lorraine Yeo1, Julia Spengler1, Banesa de Paz1,
Rowan Hardy2, Mark Cooper3, Karim Raza1,4, Christopher D. Buckley1,4 and Andrew Filer1,5*
Abstract
Background: Synovial fibroblasts play a key role in joint destruction and regulation of the inflammatory infiltrate in
established rheumatoid arthritis (RA). The mechanisms by which this occurs in the earliest stages of RA are largely
unknown. We investigated the role of Dickkopf-related protein 1 (DKK1) produced by synovial fibroblasts of patients
with very early rheumatoid arthritis (VeRA).
Methods: Fibroblasts were isolated from the disease-modifying anti-rheumatic drug–naive Birmingham early
arthritis cohort of patients with new onset of clinically apparent arthritis and inflammatory symptoms of ≤12 weeks’
duration, who at follow-up had either resolving arthritis or RA. Endothelial fibroblast co-cultures were formed using
porous filters, and lymphocyte adhesion to co-cultures was assessed using phase-contrast microscopy. DKK1 gene
expression and secretion were quantified by quantitative polymerase chain reaction and enzyme-linked
immunosorbent assay, respectively.
Results: Synovial fibroblasts from patients with VeRA expressed significantly higher levels of DKK1 messenger RNA than
those from patients with resolving arthritis. A similar trend was observed for DKK1 protein secretion. In co-culture constructs,
more DKK1 tended to be secreted in co-cultures incorporating fibroblasts from VeRA than in co-cultures from non-inflamed
joints and resolving arthritis. DKK1 secretion during co-culture positively correlated with lymphocyte adhesion.
Conclusions: Alterations in DKK1 could be involved in the pathogenesis and perpetuation of the inflammatory
response in the earliest clinically apparent stages of RA.
Keywords: DKK1, Synovial fibroblasts, Early inflammatory arthritis, Lymphocyte adhesion
Background
Clinical studies have shown that early aggressive treatment
of rheumatoid arthritis (RA) leads to better clinical out-
comes without unacceptably high adverse event profiles
[1]. The concept of an early window of opportunity is fur-
ther supported by evidence of a distinct and transient
cytokine profile in the synovial fluid of patients with RA
of less than 3 months’ duration [2]. However, disease
mechanisms during this very early stage of RA develop-
ment remain largely undefined.
In established RA, multiple epigenetic changes drive the
acquisition of a pathogenic phenotype in synovial fibro-
blasts that underpins their aberrant behaviour [3, 4]. This
pathogenic phenotype is evidenced by the ability to invade
human cartilage in a severe combined immunodeficiency
model of arthritis [5, 6]. Additionally, rheumatoid synovial
fibroblasts secrete proteases (e.g., matrix metalloprotein-
ases and cathepsins) that degrade cartilage and bone tissue
[7, 8]. Furthermore, they alter the dynamics of bone repair
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by releasing receptor activator of nuclear factor κB ligand
(RANKL), causing osteoclast differentiation leading to bone
erosion [9] whilst simultaneously producing Dickkopf-
related protein 1 (DKK1) to inhibit osteoblast-driven repair
of these erosions [10].
DKK1 is an inhibitor of the Wingless (Wnt) signalling
pathway that has been proposed as a master regulator of
joint remodelling [10]. Serum levels of DKK1 positively
correlate with joint erosions and inflammation in RA
[11]. Indeed, patients with a genetic variant of DKK1
which results in higher DKK1 serum levels have more
progressive joint destruction [12], suggesting a funda-
mental role for DKK1 in the pathogenesis of RA. Treat-
ment with antibodies against DKK1 has restored bone
loss in murine models of arthritis [10], suggesting it has
promise as a novel therapeutic target. In this study, to
determine the role of DKK1 in the pathogenesis of early
RA, we analysed, for the first time to our knowledge, the
expression of DKK1 in synovial fibroblasts from patients
with early arthritis that eventually resolved compared
with patients whose arthritis developed into RA.
Methods
Patients
Synovial tissue samples were obtained by ultrasound-
guided biopsy [13, 14] from patients recruited into the
Birmingham early arthritis cohort (BEACON). BEACON
is a cohort of disease-modifying anti-rheumatic drug
(DMARD)-naive patients with clinically apparent synovitis
in at least one joint and inflammatory joint symptoms
(morning stiffness and/or inflammatory joint pain and/or
swelling) of ≤12 weeks’ duration. Patients were assigned to
one of two outcome categories at 18-month follow-up:
resolving arthritis (n = 11) or RA (n = 14) (fulfilling 2010
American College of Rheumatology/European League
Against Rheumatism [ACR/EULAR] criteria) [15]. Patients
in the RA group are henceforth referred to as patients
with very early rheumatoid arthritis (VeRA). Resolving
arthritis was defined as no clinically apparent joint swell-
ing with no DMARD or steroid use in the previous 3
months. In addition, healthy synovial tissue samples were
collected from subjects undergoing exploratory arthros-
copy for unexplained joint pain with no macro- or micro-
scopic evidence of inflammation. Synovial fibroblasts were
isolated as previously described [16] and used between
passages 3 and 6 [17]. Demographic and clinical parame-
ters, including age, sex, symptom duration, tender and
swollen joint counts, erythrocyte sedimentation rate, C-
reactive protein, rheumatoid factor and anti-cyclic citrulli-
nated peptide status, were recorded.
Quantification of DKK1
Fibroblast messenger RNA (mRNA) was extracted using
the RNeasy Mini Kit (QIAGEN, Manchester, UK), and
DKK1 expression was analysed by Applied Biosystems
TaqMan low-density array (Life Technologies, Paisley,
UK) using an Applied Biosystems 7900HT real-time poly-
merase chain reaction machine (Life Technologies). DKK1
levels were expressed relative to GADPH using the 2−ΔΔCt
method. DKK1 levels in serum and culture supernatants
were quantified using the VersaMAP immunoassay or the
DKK1 DuoSet enzyme-linked immunosorbent assay (R&D
Systems, Abingdon, UK).
Flow-based adhesion assay
Endothelial cells were isolated from umbilical cords as de-
scribed elsewhere [18]. Endothelial fibroblast co-cultures
were established on opposite sides of 0.4-μm-pore Trans-
well inserts (BD Biosciences, Oxford, UK) [17] for 24 h
before treatment with 100 U/ml tumour necrosis factor-α
(R&D Systems) and 10 ng/ml interferon-γ (PeproTech,
London, UK) for a further 24 h. Filters were incorporated
into a parallel plate chamber, and purified peripheral
blood lymphocytes (2 × 106 cells/ml) were perfused for 4
minutes as described elsewhere [17]. Digitised recordings
were made of five random fields and analysed using
Image-Pro Plus software (Media Cybernetics, Cambridge,
UK). The number of adherent lymphocytes was averaged
per field and expressed per square millimetre per 106 cells
perfused (Fig. 2b) [17].
Ethical approval
All human samples were obtained with written informed
consent and approval from the Human Biomaterial Re-
source Centre (Birmingham, UK), West Midlands and
Black Country Research Ethics Committee or University
of Birmingham Local Ethical Review Committee.
Statistical analysis
Data analyses were performed using PASW 20.0 (SPSS,
Chicago, IL, USA) and Prism 5 (GraphPad Software, La
Jolla, CA, USA) software. Data were expressed as per-
centages, mean ± standard error of the mean and median
(interquartile range) as appropriate. Two-group compar-
isons were performed using the χ2 test, unpaired t test
and Mann-Whitney U test for categorical, parametric
continuous and non-parametric continuous data, respect-
ively. Three-group comparisons were performed with the
Kruskal-Wallis test and Dunn’s post-test. Correlations
were performed using Spearman’s test, where the r value
relates to the non-parametric Spearman’s correlation coef-
ficient. p Values less than 0.05 were considered statistically
significant.
Results
The demographic and clinical characteristics of patients
in both outcome groups are shown in Table 1. Patients
in the VeRA group were older, and a significantly higher
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number of them were female, compared with patients in
the resolving group (9 vs. 3, respectively; p < 0.001).
Patients with VeRA had more severe disease activity, as
evidenced by higher tender joint counts (7.9 vs. 2.6, p =
0.02) and swollen joint counts (7.3 vs. 3.0, p = 0.04),
higher disease activity scores (Disease Activity Score in
28 joints based on erythrocyte sedimentation rate 4.9 vs.
3.5, p = 0.004) and higher number of radiographic ero-
sions at baseline (1 vs. 0, p < 0.001) than the patients in
the resolving group. Seven of the fourteen patients in
the VeRA group were undifferentiated at the time of bi-
opsy (ACR/EULAR 2010 score <6). Fibroblasts from two
male and two female individuals undergoing exploratory
arthroscopy for unexplained joint pain with no macro-
or microscopic evidence of inflammation were included
as controls for co-culture recruitment assays (mean age
45.8 years, standard deviation 10.3).
Synovial fibroblasts from patients with VeRA expressed
significantly higher levels of DKK1 mRNA compared with
those with resolving arthritis (Fig. 1a). A similar trend was
observed for DKK1 secretion (Fig. 1b). Expression of
DKK1 mRNA did not correlate with age, disease duration
or any other clinical indices. There was no difference in
DKK1 mRNA expression between patients with VeRA
presenting with undifferentiated arthritis and those fulfill-
ing criteria at presentation (data not shown). In contrast,
serum levels of DKK1 were similar between the clinical
outcome groups (Fig. 1c).
Next we assessed whether the differential expression
of DKK1 in early disease had functional consequences.
Endothelial fibroblast co-cultures were analysed for
Table 1 Demographic, clinical and laboratory characteristics of
patients in each outcome group
Resolving arthritis
(n = 11)
VeRA (n = 14) p Value
Age, yr 37.4 ± 10.3 52.9 ± 9.5 0.001
Female, n (%) 3 (27.3) 9 (64.3) <0.0001
Disease duration, wk 4.4 ± 2.9 6.1 ± 3.3 0.210
CCP-positive, n (%) 0 (0) 7 (50) <0.0001
RF-positive, n (%) 0 (0) 6 (42.9) <0.0001
TJC28 2.6 ± 2.0 7.9 ± 5.8 0.008
SJC28 2.7 ± 2.0 7.3 ± 5.3 0.011
CRP 8.4 ± 8.1 23.0 ± 27.0 0.097
ESR 16.4 ± 15.5 31.1 ± 22.4 0.075
VAS 42.3 ± 32.1 46.9 ± 28.1 0.703
DAS28-ESR 3.5 ± 1.0 4.9 ± 1.2 0.004
Radiographic erosions, n (%) 0 (0) 1 (7.1) <0.0001
VeRA very early rheumatoid arthritis, CCP cyclic citrullinated peptide, RF
rheumatoid factor, TJC28 28-joint tender joint count, SJC28 28-joint swollen joint
count, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28-ESR
Disease Activity Score in 28 joints based on erythrocyte sedimentation rate, VAS
visual analogue scale
Data are presented as mean ± standard deviation unless otherwise indicated
Fig. 1 Dickkopf-related protein 1 (DKK1) expression in synovial
fibroblasts. Gene expression (a) and secretion (b) of DKK1 were
assessed in synovial fibroblasts isolated from patients with resolving
arthritis or very early rheumatoid arthritis (VeRA). c Serum levels of
DKK1 were assessed in patients with resolving arthritis or VeRA. Data
are the median and interquartile range for 9 (resolving) and 12
(VeRA) independent experiments. *p < 0.05 by Mann-Whitney U test.
mRNA messenger RNA
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DKK1 secretion and for their ability to support lympho-
cyte adhesion from flow (Fig. 2b). In this model, more
DKK1 was secreted in co-cultures incorporating fibro-
blasts from patients with VeRA compared with those
from non-inflamed joints (normal) or patients with
resolving disease, although this was not statistically sig-
nificant (Fig. 2a). VeRA fibroblast co-cultures released
significantly higher amounts of DKK1 than endothelial
cells cultured alone (Fig. 2a). DKK1 secretion during co-
culture showed a positive correlation with the level of
lymphocyte adhesion supported by co-culture (Fig. 2c).
Discussion
In this study, we examined, for the first time to our know-
ledge, the expression of DKK1 in synovial fibroblasts iso-
lated from DMARD-naive patients with inflammatory
arthritis of less than 3 months’ duration. Our data suggest
that, even at this very early stage, fibroblasts from patients
with VeRA may have gained the capacity to impair bone
repair and induce bone erosion through increased expres-
sion of DKK1. Notably, this pathogenic phenotype was
not observed in fibroblasts from patients with resolving
arthritis where non-RA joint inflammation was also
present. We also observed an association between DKK1
expression and the ability of fibroblasts from patients with
VeRA to perpetuate the inflammatory response through
lymphocyte adhesion. Whilst no causal relationship can
be inferred, raised DKK-1 levels may help to provide an
explanation for the long-observed association between in-
flammation and bone destruction. Collectively, these data
indicate that DKK1 expression may be involved in early
RA pathogenesis, through both the perpetuation of the in-
flammatory response and enhanced joint destruction.
DKK1 directly impairs osteoblast differentiation and in-
directly enhances bone destruction by increasing RANKL-
induced osteoclastogenesis [10, 19]. In established RA,
expression of DKK1 within the synovium localises to
synovial fibroblasts ex vivo [10] and is tightly regulated by
glucocorticoid metabolism in vitro [20], supporting a role
for Wnt signalling inhibition in RA bone destruction. In the
work we present, differential expression of DKK1 in resolv-
ing and early persistent disease suggests that increased
Fig. 2 Dickkopf-related protein 1 (DKK1) levels in human umbilical vein endothelial cell (HUVEC) synovial fibroblast co-cultures. a DKK1 release from
tumour necrosis factor (TNF)-α + interferon (IFN)-γ-treated endothelial cells cultured alone (none; n = 7) or with synovial fibroblasts from non-inflamed
joints (n = 4), patients with resolving rheumatoid arthritis (RA; n = 5) or patients with very early rheumatoid arthritis (VeRA; n = 5). Significantly higher
DKK1 levels were observed in the supernatant of VeRA-HUVEC co-cultures than HUVEC alone (p < 0.01). No statistical differences were found between
the different co-culture constructs. Data are shown as mean and standard error of the mean. Kruskal-Wallis test with Dunn’s post-test analysis were
performed. **p < 0.01. b Photomicrographs showing lymphocyte adhesion to (i) endothelial cells cultured alone, with fibroblasts from (ii) patients with
resolving RA or (iii) patients with VeRA in response to TNF-α + IFN-γ treatment. The number of adherent lymphocytes was averaged per field and is
expressed per square millimetre per 106 cells perfused. Arrows indicate adherent lymphocytes. c DKK1 release positively correlated with lymphocyte
adhesion to cytokine-treated co-cultures (p = 0.0054). Correlation assessed by Spearman’s test with a non-parametric correlation coefficient of
r = 0.7129. Each independent experiment incorporated a different donor for all cell types
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DKK1 production could be a key event in progression to
RA and occurs early in the disease process. Wnt signalling
inhibition by DKK1 may therefore be an as yet undefined
pathway through which synovial fibroblasts influence bone
destruction in early RA. Further work in this area should be
directed towards confirmation of findings in in vivo models
of arthritis.
Conclusions
Synovial fibroblasts of patients with early inflammatory
arthritis that persists as RA express higher DKK1 levels
than those from patients with inflamed joints whose
arthritis resolves. This phenomenon is amplified by co-
culture with endothelial cells and associates with in-
creased lymphocyte adhesion to co-cultures. We propose
that DKK1 expression may be involved in early RA
pathogenesis, through both perpetuation of the inflam-
matory response and enhanced joint destruction. Target-
ing of DKK1 may be a valid therapeutic approach early
in the disease course.
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